187 related articles for article (PubMed ID: 20332466)
1. Epigenetic modifiers as anticancer drugs: effectiveness of valproic acid in neural crest-derived tumor cells.
Papi A; Ferreri AM; Rocchi P; Guerra F; Orlandi M
Anticancer Res; 2010 Feb; 30(2):535-40. PubMed ID: 20332466
[TBL] [Abstract][Full Text] [Related]
2. Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
Facchetti F; Previdi S; Ballarini M; Minucci S; Perego P; La Porta CA
Apoptosis; 2004 Sep; 9(5):573-82. PubMed ID: 15314285
[TBL] [Abstract][Full Text] [Related]
3. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression.
Hofmann UB; Westphal JR; Waas ET; Zendman AJ; Cornelissen IM; Ruiter DJ; van Muijen GN
Br J Cancer; 1999 Nov; 81(5):774-82. PubMed ID: 10555745
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
Hubaux R; Vandermeers F; Crisanti MC; Kapoor V; Burny A; Mascaux C; Albelda SM; Willems L
Eur J Cancer; 2010 Jun; 46(9):1724-34. PubMed ID: 20451370
[TBL] [Abstract][Full Text] [Related]
6. Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives.
Eikel D; Lampen A; Nau H
Chem Res Toxicol; 2006 Feb; 19(2):272-8. PubMed ID: 16485903
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
[TBL] [Abstract][Full Text] [Related]
9. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line.
Lu KV; Jong KA; Rajasekaran AK; Cloughesy TF; Mischel PS
Lab Invest; 2004 Jan; 84(1):8-20. PubMed ID: 14631378
[TBL] [Abstract][Full Text] [Related]
11. Divergent effects of oncostatin M on astroglioma cells: influence on cell proliferation, invasion, and expression of matrix metalloproteinases.
Chen SH; Gillespie GY; Benveniste EN
Glia; 2006 Jan; 53(2):191-200. PubMed ID: 16206166
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory effects of retinoic acid and IIF on growth, migration and invasiveness in the U87MG human glioblastoma cell line.
Papi A; Bartolini G; Ammar K; Guerra F; Ferreri AM; Rocchi P; Orlandi M
Oncol Rep; 2007 Oct; 18(4):1015-21. PubMed ID: 17786368
[TBL] [Abstract][Full Text] [Related]
13. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
[TBL] [Abstract][Full Text] [Related]
14. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
[TBL] [Abstract][Full Text] [Related]
15. Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells.
Castro LM; Gallant M; Niles LP
J Neurochem; 2005 Dec; 95(5):1227-36. PubMed ID: 16313512
[TBL] [Abstract][Full Text] [Related]
16. Chronic administration of valproic acid inhibits PC3 cell growth by suppressing tumor angiogenesis in vivo.
Gao D; Xia Q; Lv J; Zhang H
Int J Urol; 2007 Sep; 14(9):838-45. PubMed ID: 17760752
[TBL] [Abstract][Full Text] [Related]
17. Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Poljakova J; Hrebackova J; Dvorakova M; Moserova M; Eckschlager T; Hrabeta J; Göttlicherova M; Kopejtkova B; Frei E; Kizek R; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():101-16. PubMed ID: 22167207
[TBL] [Abstract][Full Text] [Related]
18. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
[TBL] [Abstract][Full Text] [Related]
19. Neuroendocrine transdifferentiation induced by VPA is mediated by PPARgamma activation and confers resistance to antiblastic therapy in prostate carcinoma.
Angelucci A; Muzi P; Cristiano L; Millimaggi D; Cimini A; Dolo V; Miano R; Vicentini C; Cerù MP; Bologna M
Prostate; 2008 May; 68(6):588-98. PubMed ID: 18288684
[TBL] [Abstract][Full Text] [Related]
20. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
